Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Ifeanyichukwu Ifechidere: Why Fibrinolysis Matters as Much as Clot Formation
Ifeanyichukwu Ifechidere/LinkedIn
Jun 17, 2026, 17:44

Ifeanyichukwu Ifechidere: Why Fibrinolysis Matters as Much as Clot Formation

Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospitals NHS Foundation Trust, shared a post on LinkedIn:

“We spend so much time talking about how clots form. Nobody talks about what happens when they don’t dissolve.

Haemostasis has two sides.

Clot formation gets all the attention — the factors, the cascade, the platelets, the thrombin burst.

But fibrinolysis — the system that breaks clots down is equally critical. And when it fails, patients bleed catastrophically or clot relentlessly.

This is haemostasis’s forgotten half. Let’s fix that.

The Fibrinolytic System — how it works:

At the centre of fibrinolysis is a single, elegant mechanism:

Plasminogen is converted to plasmin, which then degrades fibrin.

But the elegance is in the regulation.

  • Tissue Plasminogen Activator (tPA) is released from endothelial cells in response to thrombus formation. It binds fibrin within the clot — converting plasminogen to plasmin with extraordinary specificity. Precise. Targeted. Intentional.
  • Plasmin is the engine. Once activated, it degrades fibrin into fibrin degradation products — D-dimers among them. It also degrades fibrinogen, Factor V, and Factor VIII if insufficiently regulated.
  • PAI-1 (Plasminogen Activator Inhibitor-1) is the primary brake on tPA. Elevated PAI-1 suppresses fibrinolysis — seen in obesity, metabolic syndrome, sepsis, and acute thrombotic states. High PAI-1 means clots persist longer than they should.
  • Alpha-2 Antiplasmin neutralises circulating plasmin instantly — confining fibrinolytic activity to the clot surface. When alpha-2 antiplasmin is deficient, systemic plasmin runs unchecked.

When fibrinolysis fails — in both directions:

Hyperfibrinolysis — the system accelerates beyond control:

  • Seen in trauma, liver disease, DIC, post-thrombolysis, major obstetric haemorrhage
  • Presents as uncontrolled bleeding, rapidly dissolving clots, plummeting fibrinogen
  • TEG/ROTEM signatures show characteristic lysis patterns — LY30, ML, FIBTEM amplitude loss

Hypofibrinolysis — the system is suppressed:

  • Seen in thrombotic APS, elevated PAI-1 states, COVID-19 coagulopathy, obesity
  • Clots form and persist — driving DVT, PE, microvascular thrombosis
  • Increasingly recognised as a distinct thrombotic phenotype missed by standard coagulation screens

What your standard laboratory panel misses:

PT. APTT. Fibrinogen. D-dimer.

None of these directly assess fibrinolytic capacity. D-dimer tells you fibrinolysis has occurred — not whether it is functioning optimally or pathologically.

A coagulation screen without fibrinolytic assessment is half a haemostatic picture.

Quick Poll — I want to know where you stand:

In your clinical or laboratory practice, how often is fibrinolytic function formally assessed?

  1. Regularly — we use TEG/ROTEM routinely
  2. Occasionally — in specific bleeding scenarios
  3. Rarely — standard coagulation panel only
  4. Never — we don’t have access to viscoelastic testing

Drop your answer in the comments. Let’s map the real-world gap together.

Has hyperfibrinolysis or hypofibrinolysis ever changed your clinical management?

Share below in the comment section.”

Ifeanyichukwu Ifechidere

Find more posts featuring Ifeanyichukwu Ifechidere on Hemostasis Today.

Alpha-2 Antiplasmin APS bleeding Blood Clot Formation D-dimers DIC DVT Factor V Factor VIII Fibrin fibrinogen fibrinolysis Health Hematology Hemostasis Hemostasis News Hemostasis Today Hyperfibrinolysis Hypofibrinolysis Ifeanyichukwu Ifechidere Liver Disease Medicine microvascular thrombosis PAI-1 PE Plasmin Plasminogen Plasminogen activator inhibitor-1 Sepsis TEG/ROTEM Thrombin Tissue Plasminogen Activator tPA
NewsFeed